BioAge Labs, Inc.
BioAge Labs, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 39.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 20% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 5, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 30, 2026 | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors | Trial Milestone | Phase 2 |
| November 15, 2027 | A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema | Trial Milestone | Phase 2 |
Track BIOA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BIOA in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.